Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late?
Novartis says one of its top emerging drugs spotlighted by Vas Narasimhan has come through in a Phase II trial for paroxysmal nocturnal hemoglobinuria, burnishing its prospect as an add-on — or even alternative — to Alexion’s Soliris.
Going after the alternative complement pathway, the pharma giant sees oral administration as one of LNP023’s key attractions — although analysts say it’s too late to make much of a difference in this particular rare blood disorder.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
